Combined cardiovascular disease outcomes with lisinopril versus chlorthalidone in ALLHAT

Increased relative risk of cardiovascular outcomes with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of combined cardiovascular disease outcomes in all patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of these outcomes in total and in most subgroups.